FAX PHARMA
Live / Registered — Registered (as of 15 Mar 2022)
What this means for you
Registered since 15 Mar 2022. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 88983683
- Registration number
- 6673025
- Mark type
- Design + words
- Filed
- 28 Jan 2020
- Published for opposition
- 11 May 2021
- Registered
- 15 Mar 2022
- Attorney of record
- Erik Lichter
Goods and services
- Class 042 — Scientific and technological services: Consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; Medical and scientific research in the field of cancer treatment and diagnosis; Medical and scientific research, namely, conducting clinical trials for others; Medical laboratory services; Medical research; Medical research services in the field of cancer; Pharmaceutical research and development; Providing medical and scientific research information in the field of clinical trials; Providing medical and scientific research information in the fields of pharmaceuticals and genetics; Quality evaluation services for the medical and anesthesia industries; Research and development in the pharmaceutical and biotechnology fields; Research and development of pharmaceuticals for the treatment of age-related diseases and cancer; Research and development of vaccines and medicines; Scientific investigations for medical purposes; Scientific research; Scientific research and development
Owner
- Fax Pharma Inc., Miami, FL, US
- Fax Pharma Inc., Miami, FL, US
- Fax Pharma Inc., Miami, FL, US
Prosecution history
- 15 Mar 2022 — REGISTERED-PRINCIPAL REGISTER
- 08 Feb 2022 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 07 Feb 2022 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 21 Jan 2022 — NOTICE OF DESIGN SEARCH CODE E-MAILED
- 20 Jan 2022 — STATEMENT OF USE PROCESSING COMPLETE
- 06 Jan 2022 — USE AMENDMENT FILED
- 20 Jan 2022 — DIVISIONAL PROCESSING COMPLETE
- 06 Jan 2022 — DIVISIONAL REQUEST RECEIVED
- 20 Jan 2022 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 06 Jan 2022 — TEAS REQUEST TO DIVIDE RECEIVED
- 06 Jan 2022 — TEAS STATEMENT OF USE RECEIVED
- 06 Jul 2021 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 02 Jul 2021 — POST PUBLICATION AMENDMENT - ENTERED
- 01 Jul 2021 — ASSIGNED TO PETITION STAFF
- 27 May 2021 — TEAS POST PUBLICATION AMENDMENT RECEIVED